Kyprolis Sales Drive ONXX Earnings Beat
Long Ideas - Onyx Pharmaceuticals (NASDAQ:ONXX) got the better of earnings estimates for the 3rd quarter of 2012, with non-GAAP net loss per share of $.79 compared to … Continue Reading
Read nowAuthor Archives: Jake King
ArQule Reports 3Q Results as Investors Now Look to Tivantinib’s HCC Indication
Long Ideas - Oncology-focused ArQule, Inc. (NASDAQ:ARQL) reported third quarter financial results on Thursday morning, noting that cash, equivalents, and marketable investments totaled $140M on Sept. 30, and … Continue Reading
Read nowBioCryst and Presidio’s Priorities May Shift with FDA Concerns
Quick Picks - Chalk another “nuc” up to the FDA’s growing list of safety-related development interruptions. On Tuesday, BioCryst Pharmaceuticals (NASDAQ:BCRX) announced that it has withdrawn an Investigational … Continue Reading
Read nowCatalyst Licenses New Candidate Ahead of November Data Release
Quick Picks - Catalyst Pharmaceutical Partners (NASDAQ:CPRX) climbed as much as 18% ahead of the bell Wednesday after the company announced that it has licensed the rights to … Continue Reading
Read nowExpense Cuts Ahead of a Pivotal Year for AVEO and Tivozanib
Long Ideas - In a move that management says will save the company more than $100M over the next three years, AVEO Oncology (NASDAQ:AVEO) cut its work force … Continue Reading
Read nowLexicon’s Stock Offering; In Biotech, it’s “Raise When You Can”
Long Ideas - Despite a stash of cash and liquid investments, Lexicon Pharmaceuticals (NASDAQ:LXRX) caught investors off guard two weeks ago by initiating a capital raise. The company … Continue Reading
Read nowSynribo Approval Does Little for TEVA; Second CML Drug Approved Since September
Quick Picks - Despite a new drug approval on Friday, Teva Pharmaceuticals (NYSE:TEVA) declined slightly in the trading session. The FDA approved Synribo as a treatment for Chronic … Continue Reading
Read now